Fusion Pharmaceuticals (NASDAQ:FUSN) Downgraded to Hold at Brookline Capital Management theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Truist Financial Reaffirms Hold Rating for Fusion Pharmaceuticals (NASDAQ:FUSN) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Jefferies Financial Group reaffirmed their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research report report published on Tuesday, Marketbeat reports. They currently have a $21.00 price target on the stock, up from their prior price target of $10.00. FUSN has been the topic of several other reports. William Blair […]
Royal Bank of Canada reiterated their sector perform rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $21.00 price objective on the stock, up from their previous price objective of $16.00. FUSN has been the topic of several other research […]
SVB Leerink reaffirmed their market perform rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $21.00 target price on the stock, up from their prior target price of $17.00. Several other equities analysts have also commented on […]